Literature DB >> 19428308

(125)I episcleral plaque brachytherapy in the treatment of choroidal melanoma: a single-institution experience in Spain.

Raquel Correa1, Joan Pera, Joaquín Gómez, Alfredo Polo, Cristina Gutiérrez, Josep María Caminal, Ignasi Modolell, Valenti Navarro, Ferrán Guedea.   

Abstract

PURPOSE: To analyze the results of episcleral plaque brachytherapy from the Catalan Institute of Oncology in Spain.
MATERIALS AND METHODS: From September 1996 through December 2004, 120 patients with choroidal melanoma (median age, 59 years) were treated with iodine-125 seeds at our institution. Patients were classified according to the criteria developed by the Collaborative Ocular Melanoma Study (COMS) group, as follows-COMS-I: 3 patients; COMS-II: 87 patients; COMS-III: 24 patients; and indeterminate COMS: 9 patients. Followup ranged from 1 year to 8.4 years.
RESULTS: Overall survival at 5 and 8 years was 83.9% and 73.3%, respectively. The 5- and 8-year specific survival rate was 85.7%. Local control was 88.2% and 72.7% at 5 and 8 years, respectively. The most common treatment-related toxicity was cataract formation (31.6% of cases), followed by radiation retinopathy (7.5%) and retinal detachment (4.1%).
CONCLUSION: The results of this institutional retrospective study confirm that the use of iodine-125 episcleral plaques to treat choroidal melanoma offers the potential for conserving a functioning eyeball. The toxicity profile is favorable and disease control is similar to other techniques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428308     DOI: 10.1016/j.brachy.2009.03.189

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  7 in total

1.  Episcleral brachytherapy for uveal melanoma: analysis of 136 cases.

Authors:  Ciro García-Álvarez; María Antonia Saornil; Francisco López-Lara; Ana Almaraz; María Fe Muñoz; Jesús Frutos-Baraja; Yerena Muiños
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

2.  Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients.

Authors:  Umit Yasar Guleser; Ahmet Murat Sarici; Didar Ucar; Busenur Gonen; Nilay Sengul Samanci; Mustafa Özgüroğlu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-11-04       Impact factor: 3.117

Review 3.  Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose.

Authors:  Jose J Echegaray; Nikolaos E Bechrakis; Nakul Singh; Claudine Bellerive; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-08

4.  106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma.

Authors:  Ping Jiang; Konstantine Purtskhvanidze; Gerit Kandzia; Dirk Neumann; Ulf Luetzen; Frank-André Siebert; Johann Roider; Juergen Dunst
Journal:  Radiat Oncol       Date:  2020-07-29       Impact factor: 3.481

5.  Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

6.  Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques.

Authors:  Andrew J Wong; Bin S Teh; Brandon T Nguyen; Ramiro Pino; Maria E Bretana; Eric H Bernicker; Patricia Chevez-Barrios; E Brian Butler; Amy C Schefler
Journal:  J Contemp Brachytherapy       Date:  2022-04-11

Review 7.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.